Esophageal Squamous Cell Carcinoma: all 657 studies
Page 2 of 7. Open to participants first (276), then studies with results posted, then the rest; newest registration first within each.
- Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06952621Phase 3
- Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT06912074Phase 2
- Neoadjuvant QL1706 Therapy for ESCCRecruitingNCT06908382Phase 2
- Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06907602Phase 2/3
- Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)Not yet recruitingNCT06903871Phase 2
- Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant TherapyNot yet recruitingNCT06889402
- A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for ECEnrolling by invitationNCT06863831Not applicable
- Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCCNot yet recruitingNCT06861894Phase 2
- Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCCNot yet recruitingNCT06861777Phase 2/3
- QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06852456Phase 2
- A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06843889Phase 2
- Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted TherapyRecruitingNCT06828588Early Phase 1
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Phase 1/2
- Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06756841Not applicable
- A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid TumorsRecruitingNCT06747585Phase 1/2
- Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs TherapyNot yet recruitingNCT06746961Phase 1/2
- Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06718205Phase 2
- Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06715501Not applicable
- Tumor Regression Grade As Predictor of Adjuvant TherapyRecruitingNCT06710665
- A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)RecruitingNCT06709417Phase 2
- Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06703047Phase 2
- Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell CarcinomaRecruitingNCT06698692
- Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06692270Phase 2
- Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell CarcinomaRecruitingNCT06690476Early Phase 1
- Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06684600Phase 2
- Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)Not yet recruitingNCT06681285Phase 2
- Neoantigen Vaccines in Esophageal Squamous Cell CarcinomaRecruitingNCT06675201Phase 2
- Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles StudyRecruitingNCT06663059Phase 2
- A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid TumorsRecruitingNCT06657144Phase 1
- A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell CarcinomaNot yet recruitingNCT06656091Phase 3
- Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06646588Phase 2
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Phase 3
- Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Phase 2
- Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCCRecruitingNCT06603402Phase 2
- Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative RadioimmunotherapyRecruitingNCT06602843Not applicable
- Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingNCT06601309Phase 2
- Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal CancerNot yet recruitingNCT06599775Phase 2
- Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06596954Not applicable
- BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06588335Phase 2
- Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT06576973Phase 2
- Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06563869Phase 3
- Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)RecruitingNCT06561178
- Study of XB010 in Subjects With Solid TumorsRecruitingNCT06545331Phase 1
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsRecruitingNCT06535607Phase 2
- A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06512428Phase 2
- Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCCRecruitingNCT06510660Phase 2
- Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）RecruitingNCT06509568Phase 2
- Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCCNot yet recruitingNCT06508229Phase 2
- Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCCNot yet recruitingNCT06501664Phase 3
- Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06491134Phase 1
- Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06490003
- AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma PatientsRecruitingNCT06489197Phase 2
- A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06487702Phase 2
- Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCCEnrolling by invitationNCT06475196
- Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06468670Phase 2
- Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06468644Phase 2
- A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06463834Phase 2
- Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.RecruitingNCT06452602Phase 2
- Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06446726Phase 2
- Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06429865Not applicable
- Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06426797Phase 2
- Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06422858Phase 2
- Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06413342Phase 2
- Multimodal Endoscopic Image Fusion for Assessing Infiltration in Superficial Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06412419
- Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and TislelizumabRecruitingNCT06408584
- Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06388135Phase 4
- Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)RecruitingNCT06385730Phase 2
- A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06356688Phase 2
- A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06354530Phase 2/3
- PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDYRecruitingNCT06354140Phase 2
- Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06339619Phase 2
- Sacituzumab Govitecan for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06329869Phase 2
- Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell CarcinomaRecruitingNCT06304350Phase 2
- Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06303583Phase 1/2
- Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of ImmunotherapyRecruitingNCT06272214Phase 2
- Outcomes of Smoker and Drinker With Esophageal Squamous Cell Carcinoma After EsophagectomyRecruitingNCT06269341
- Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramRecruitingNCT06265285Phase 2
- Accurate Diagnosis of the Invasion Depth in ESCC by a Deep Neural Network Analysis of NBI Endoscopy DataNot yet recruitingNCT06252974
- A Study of MGC026 in Participants With Advanced Solid TumorsRecruitingNCT06242470Phase 1
- Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell CarcinomasRecruitingNCT06225921Phase 1
- A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerRecruitingNCT06194734Phase 3
- Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell CancerRecruitingNCT06190847
- Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 InhibitorRecruitingNCT06190782Phase 3
- A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCCRecruitingNCT06190639Phase 2
- Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)RecruitingNCT06187597Phase 2
- PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCCRecruitingNCT06186609Phase 2
- Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical TrialNot yet recruitingNCT06178211Phase 2
- Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal CancerRecruitingNCT06173986Phase 1/2
- Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal NeoplasmsRecruitingNCT06169163
- Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical ResectionNot yet recruitingNCT06161909Phase 3
- A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06160557
- A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06152978Phase 2
- Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.Not yet recruitingNCT06143722Phase 2
- Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal CancerRecruitingNCT06138028Phase 2/3
- Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.RecruitingNCT06125262
- Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell CarcinomaRecruitingNCT06122493Phase 2
- Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06103890
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400RecruitingNCT06084481Phase 1
- IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)Not yet recruitingNCT06078657Phase 2
- Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell CarcinomaRecruitingNCT06056336Phase 2